Lymphopenia is a condition in which there is a lower-than-normal number of lymphocytes (a type of white blood cell) in the blood. Also called lymphocytic leukopenia and lymphocytopenia.
A recent case study published in the Journal of Applied Laboratory Medicine in August 2020 illustrates this with its finding of persistent seronegativity in a patient confirmed to be SARS-CoV-2 positive.
Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection often complain of fatigue, but now a new study shows that it also causes severe and frequent fatigue in those who recover after mild illness too.
Now, a new study by researchers at Saarland University, Germany, and published on the preprint server medRxiv in July 2020 shows that there are higher levels of anti-SARS-CoV-2 T cells, which show significant alterations in the phenotype and function.
A cellular therapy tested on 13 intubated patients with mechanical ventilation has shown to be efficient for the clinical improvement of critical cases of COVID-19.
As experts in hematology HORIBA UK Ltd, Medical announces that the Company has published a white paper entitled, ‘COVID-19 screening, prognosis and severity assessment with biomarkers for management of patients’.
A new study published on the preprint server medRxiv in June 2020 describes differences in the adaptive and innate immune response in mild, moderate, and severe COVID-19. This may mean that permanent immune responses occur only in patients who recover from severe COVID-19.
A new study published on the preprint server bioRxiv in June 2020 shows that T cell responses in COVID-19 patients are broader and more robust in severe disease and are explicitly directed against spike, memory, and ORF3a proteins.
A new study by researchers in the Netherlands and published on the preprint server bioRxiv in June 2020 describes the differences in T and B cell responses seen in patients with severe COVID-19.
A new study published on the preprint server medRxiv in June 2020 shows that immune cells, antibody levels, cytokine levels, and viral loads contribute to the sex difference seen in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Spain is one of the European countries besides the UK and Italy that was particularly hard hit by the coronavirus pandemic in March.
A new report by researchers from Thailand's Mahidol University and published on the preprint server medRxiv in May 2020 reports that the clinical severity of COVID-19 may be linked to the genetic makeup of the patient in addition to external factors.
An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial,” was published as a pre-proof for the Journal of Allergy and Clinical Immunology.
The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.
A transgenic mouse developed at Cincinnati Children's to model the deadly childhood immune disease HLH (hemophagocytic lymphohistiocytosis) may play a key role in saving lives during the COVID-19 virus pandemic.
The hypothesis that blood clotting disorders may explain some of the worst symptoms of COVID-19, including respiratory failure and pulmonary fibrosis, was suggested in mid-April by researchers in Brazil affiliated with the University of São Paulo's Medical School (FM-USP) via an article accepted for publication by the Journal of Thrombosis.
A new case report released on the preprint server medRxiv* provides a detailed longitudinal analysis of the immune response associated with a fatal case of coronavirus disease (COVID-19). It highlights the need for addressing the source of hyper inflammation in the treatment approach.
Q (Prof. Singer): What do you think about the comorbidities and the age of the patients in the treatment of COVID-19? Is the mortality higher in elderly patients as it is reported from recent papers?
Emerging concerns that common antihypertensive treatment approaches with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) – jointly known as renin-angiotensin-aldosterone system (RAAS) inhibitors – may exert a negative effect in COVID-19 patients are not grounded in scientific evidence, as reported by researchers in a recent review article published in Mayo Clinic Proceedings journal.
A study published in the journal The Lancet in March 2020 reports on three clusters of COVID-19 that happened in Singapore in February 2020. The first was because of a tour group, the second a company conference, and the third a church gathering.
A new phase II trial finds that a combination of radiation therapy and immunotherapy led to encouraging survival outcomes and acceptable toxicity for patients with locally advanced head and neck squamous cell carcinoma